Halozyme Therapeutics has struck a new global collaboration with Takeda, expanding the reach of its ENHANZE drug delivery technology to support Takeda’s blockbuster inflammatory bowel disease therapy vedolizumab, marketed as ENTYVIO.

 

The agreement, signed in December 2025, grants Takeda an exclusive worldwide license to use Halozyme’s proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20) with vedolizumab, a biologic used to treat ulcerative colitis and Crohn’s disease. The deal underscores growing demand for drug delivery technologies that can reduce treatment burden and improve convenience for patients with chronic conditions.

 

“Our collaboration with Takeda reflects our ongoing commitment to delivering innovative solutions that enhance the patient experience, with the goal of helping patients spend less time managing their therapy and more time living their lives,” said Dr Helen Torley, President and Chief Executive Officer of Halozyme. 

 

“Our new collaboration reinforces the broad applicability and value of the ENHANZE technology across multiple therapeutic areas.”

 

Takeda framed the partnership as a strategic move to better serve patients and clinicians managing inflammatory bowel disease (IBD), a category with rising global prevalence.

 

“People living with ulcerative colitis and Crohn's disease, as well as their health care providers, need flexible treatment options that match evolving needs and priorities in disease management,” said Robert Hollowell, Head of Global Product and Launch Strategy, GI and Inflammation at Takeda. 

 

“Our collaboration is another example of our commitment to the IBD community and leadership in this therapeutic area. It is an exciting opportunity to potentially enable vedolizumab to benefit even more patients around the world, and integrate even more seamlessly into patients' lives.”

 

Financial terms include an upfront payment to Halozyme, potential development and commercial milestone payments, and tiered royalties in the low-to-mid single-digit range on sales of ENHANZE-enabled vedolizumab products.

 

Crohn’s disease and ulcerative colitis, the two primary forms of IBD, are marked by chronic gastrointestinal inflammation and can lead to serious complications. More than 10 million people worldwide are expected to be living with IBD within the next decade, highlighting the growing burden of the disease and the need for scalable treatment innovations.